Biotech Consultancy Services

biotechconsultancy.net

Headquartered in Singapore, BCS provided specialist advice that focused on technical and commercial management strategies into the agri-biotechnology industry. The founder, Edward Manchester, is now engaged as Regional Director with Biomin Asia, based in Singapore.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MedTech, Industrial Impact

MAXCYTE LICENCES WITH CATAMARAN BIO TO ADVANCE ITS CAR-NK CELL THERAPY PROGRAMS

MaxCyte | January 04, 2023

news image

MaxCyte, a leading commercial cell-engineering company, announced the signing of a strategic platform license (SPL) with Catamaran Bio, a biotechnology enterprise creating off-the-shelf chimeric antigen receptor (CAR)-NK cell therapeutics to cure a wide range of cancers. While Catamaran acquires non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform per the terms of the agreement, in exchange, MaxCyte will ...

Read More

CONCERTAI CREATES COVID-19 RESOURCES FOR ONCOLOGY TO SUPPORT HEALTHCARE PROVIDERS, BIOPHARMACEUTICAL INNOVATORS, AND BIOMEDICAL RESEARCHERS

ConcertAI | October 08, 2020

news image

ConcertAI has launched a set of COVID-19 resources for oncology to support the needs of healthcare providers, biopharmaceutical innovators, and biomedical researchers as they look to maintain patient access to new and critical treatments and improve outcomes during this pandemic. Abstracted sets of aggregated, de-identified real-world data (RWD) will be derived from CancerLinQ Discovery™– a project of CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clin...

Read More

Medical

FAUNA BIO'S COMPARATIVE GENOMICS APPROACH FINDS NEW COMPOUNDS FOR HEART AND LUNG DISEASES

Fauna | June 15, 2022

news image

Fauna Bio, a biotechnology company pioneering the fields of comparative, computational and translational genomics, is celebrating its fourth birthday this month with the release of Centaur, a knowledge graph that is the first of its kind to visualize the intersection between animal gene expression data and human diseases in one comprehensive map. With Centaur, Fauna Bio is able to more rapidly identify human disease indications and targets to generate new therapeutic solutions for some of the mo...

Read More

NOVARTIS TAPS ORIONIS TO PURSUE 'HISTORICALLY ELUSIVE TARGETS'

FierceBiotech | March 06, 2020

news image

Novartis has entered into a four-year research collaboration with Orionis Biosciences. The agreement tasks Orionis with applying its technologies to “historically elusive targets” in multiple therapeutic areas. Orionis has been around since 2015 but kept a low profile over most of that time. The transatlantic biotech used its time flying below the radar to establish two platforms, one focused on cytokines and another for “genome-scale drug discovery,” and to use them to g...

Read More
news image

MedTech, Industrial Impact

MAXCYTE LICENCES WITH CATAMARAN BIO TO ADVANCE ITS CAR-NK CELL THERAPY PROGRAMS

MaxCyte | January 04, 2023

MaxCyte, a leading commercial cell-engineering company, announced the signing of a strategic platform license (SPL) with Catamaran Bio, a biotechnology enterprise creating off-the-shelf chimeric antigen receptor (CAR)-NK cell therapeutics to cure a wide range of cancers. While Catamaran acquires non-exclusive clinical and commercial rights to use MaxCyte's Flow Electroporation® technology and ExPERT™ platform per the terms of the agreement, in exchange, MaxCyte will ...

Read More
news image

CONCERTAI CREATES COVID-19 RESOURCES FOR ONCOLOGY TO SUPPORT HEALTHCARE PROVIDERS, BIOPHARMACEUTICAL INNOVATORS, AND BIOMEDICAL RESEARCHERS

ConcertAI | October 08, 2020

ConcertAI has launched a set of COVID-19 resources for oncology to support the needs of healthcare providers, biopharmaceutical innovators, and biomedical researchers as they look to maintain patient access to new and critical treatments and improve outcomes during this pandemic. Abstracted sets of aggregated, de-identified real-world data (RWD) will be derived from CancerLinQ Discovery™– a project of CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clin...

Read More
news image

Medical

FAUNA BIO'S COMPARATIVE GENOMICS APPROACH FINDS NEW COMPOUNDS FOR HEART AND LUNG DISEASES

Fauna | June 15, 2022

Fauna Bio, a biotechnology company pioneering the fields of comparative, computational and translational genomics, is celebrating its fourth birthday this month with the release of Centaur, a knowledge graph that is the first of its kind to visualize the intersection between animal gene expression data and human diseases in one comprehensive map. With Centaur, Fauna Bio is able to more rapidly identify human disease indications and targets to generate new therapeutic solutions for some of the mo...

Read More
news image

NOVARTIS TAPS ORIONIS TO PURSUE 'HISTORICALLY ELUSIVE TARGETS'

FierceBiotech | March 06, 2020

Novartis has entered into a four-year research collaboration with Orionis Biosciences. The agreement tasks Orionis with applying its technologies to “historically elusive targets” in multiple therapeutic areas. Orionis has been around since 2015 but kept a low profile over most of that time. The transatlantic biotech used its time flying below the radar to establish two platforms, one focused on cytokines and another for “genome-scale drug discovery,” and to use them to g...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us